文献速递抗栓抗凝管理

巴西患者华法林治疗依从性评估工具(TAAW)的开发与验证

Development and validation of a tool assessing adherence to warfarin therapy (TAAW) by Brazilian patients.
PubMed 文献 · Br J Clin Pharmacol · 2026-02-04

本研究开发并验证了多维度的华法林治疗依从性评估工具(TAAW),涵盖华法林摄入、自我护理和健康监测三个维度。经过专家评估、语义分析和心理测量学验证,最终版包含21个条目,具有优秀的内部一致性(Cronbach's alpha=0.98)、高重测信度(ICC=0.96)以及与治疗目标范围内时间(TTR)的强相关性(Spearman's rho=0.91),可用于临床和研究场景评估依从性模式。

要点

  • TAAW包含21个条目,覆盖华法林摄入、自我护理和健康监测三个维度。
  • TAAW的Cronbach's alpha为0.98,ICC为0.96,与TTR的Spearman's rho为0.91。
  • 该工具可用于识别依从性模式,辅助制定针对性干预以优化抗凝结局。

核心结论

  • 验证后的TAAW是评估华法林治疗依从性的可靠工具,适用于临床和研究场景。

研究设计与样本

  • 工具开发包括概念图构建、初步版本制定、专家评估、30名参与者预测试的语义分析以及心理测量学验证。
  • 心理测量学验证包括探索性因子分析、内部一致性、重测信度和假设检验。

主要发现

  • 初始35个条目中,14个被剔除,19个被修改,最终版为21个条目。
  • 最终版条目分布于三个维度:华法林摄入(n=10)、华法林使用相关自我护理(n=7)和健康监测(n=4)。
  • TAAW显示出单维结构,内部一致性优秀(Cronbach's alpha=0.98)。
  • 重测信度高(ICC=0.96),与TTR强相关(Spearman's rho=0.91)。

临床怎么用

  • 临床药师可使用TAAW评估华法林治疗依从性,识别依从性模式并实施针对性干预。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To develop and validate a multidimensional tool to assess adherence to warfarin therapy by Brazilian patients. METHODS: A Tool for Assessing Adherence to Warfarin Therapy (TAAW) was designed to encompass warfarin intake and other treatment-related aspects, including causal and effect items of adherence. The development process included: (i) construction of a concept map; (ii) elaboration of a preliminary version; (iii) expert assessment; (iv) semantic analysis through pre-testing with 30 participants; and (v) psychometric validation, including exploratory factor analysis, internal consistency, test-retest reliability and hypothesis testing. RESULTS: Of the 35 initially drafted items, 14 were discarded and 19 modified, resulting in a final version with 21 items distributed across three dimensions: warfarin intake (n = 10), self-care associated with warfarin use (n = 7) and health monitoring (n = 4). The TAAW tool demonstrated a unidimensional structure, excellent internal consistency (Cronbach's alpha = 0.98), high test-retest reliability (Intraclass Correlation Coefficient = 0.96) and strong correlation with the time in therapeutic range (Spearman's rho = 0.91), confirming its validity and reliability. CONCLUSION: The validated TAAW is a robust instrument for assessing adherence to warfarin therapy in clinical and research settings. Its comprehensive approach allows for the identification of adherence patterns, enabling healthcare professionals to implement targeted interventions and optimize anticoagulation outcomes.

来源:Br J Clin Pharmacol,查看原文。版权归原作者所有。

引用

  1. Ferreira CB, Vianna MS, Pagano AS, et al. Development and validation of a tool assessing adherence to warfarin therapy (TAAW) by Brazilian patients. Br J Clin Pharmacol. 2026. PMID: 41639601. doi:10.1002/bcp.70467

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。